Shares of cancer-therapy company Forty Seven Inc. shot up more than 30% in after-hours trading Thursday after a report that Gilead Sciences Inc. has made a takeover offer. Bloomberg News reported that Gilead and Forty Seven, a biotech firm that specializes in cancer immunotherapy, are discussing a number of options, including a partnership, and the company was said to have other suitors as well. Forty Seven's stock is up 192% over the past year, with a market cap of around $2.3...
SAN DIEGO, Feb. 27, 2020 TOCAGEN INC. (TOCA), a clinical-stage, cancer-selective gene therapy company, today reported financial results and business highlights for the fourth quarter and full year ended December 31, 2019.
MORRISTOWN, N.J., Feb. 27, 2020 Currax Pharmaceuticals, LLC, a specialty biopharmaceutical company dedicated to expanding access to clinically differentiated, underappreciated medicines both branded and generic today provided an update on its business and financial performance for the period of May to December 2019.
SAN FRANCISCO, Feb. 27, 2020 The global 3D cell culture market size is expected to reach USD 3.2 billion by 2027, expanding at a CAGR of 11.3%, according to a new report by Grand View Research, Inc. A rise in the adoption of in-vivo models for a better understanding of cell behavior is anticipated to fuel market growth.
NEW YORK, Feb. 26, 2020 Arsenal Capital Partners, a leading private equity firm investing in healthcare and specialty industrials companies, announced today the acquisition of BresMed Health Solutions, a pioneer in providing health economic research, communications, and consulting services to the global pharmaceutical industry.
Acquisition to expand Fluidigms industry-leading mass cytometry capabilities and address flow cytometry markets with the addition of fully automated sample prep Fluidigm Corporation (FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, announced today that it has completed the acquisition of InstruNor AS, the privately held provider of ...
Strongbridge Biopharma plc (SBBP): * REPORTS FOURTH QUARTER AND FULL-YEAR 2019 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE. * Q4 NON-GAAP LOSS PER SHARE $0.25. * Q4 GAAP LOSS PER SHARE $0.17. * Q4 EARNINGS PER SHARE ESTIMATE $-0.26 -- REFINITIV IBES DATA. * SEES FY 2020 REVENUE $26 MILLION TO $27 MILLION Source text for Eikon: Further company coverage:
SALT LAKE CITY, Feb. 25, 2020 Lipocine Inc. (LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that it has entered into securities purchase agreements with certain institutional investors providing for the purchase and sale of 10,084,034 Class A Units at an offering price of $0.595 per unit, with each Class A Unit consisting of one share of...
LOVELAND, Colo. Point of Care Lab Diagnostics for 2019 Heska's POC Lab Consumables grew 19.7%, which was strongly above 2019 Outlook. Heska's (HSKA) sixth year of net market share gains in end-user hospitals. Strong retention and extensions of total Heska Reset subscribers. Growth strongly above 2019 Outlook in Months Under Subscription and other key targets.
Acquisition will spur the development of new drugs to treat complex neurodegenerative conditions, including Alzheimers and Parkinsons disease Certara®, the global model-informed drug development and decision support leader, today reported that it has acquired a range of modeling and simulation technology assets from In Silico Biosciences, Inc. The assets include a platform of multiple integra...
News, commentary and research reports are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.
PDF’s require Adobe® Reader® and will open in a new window.
